We are live on ! Find out more

Alto Neuroscience

ANRO

Market cap $858M

21.87 USD

-1.43

6.14%

At close Updated Nov 5, 4:00 PM EST

1 day

-6.14%

5 days

-5.77%

1 month

-8.91%

3 months

-21.98%

6 months

-14.07%

Year to date

31.83%

1 year

93.71%

5 years

5.65%

10 years

5.65%

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 68

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on November 3, 2026, the Compensation and Management Development Committee of Alto's Board of Directors granted a new employee an option to purchase 50,000 shares of Alto's common stock. The stock option was granted under Alto's 2025 Inducement Plan as a mater.

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences:Stifel 2026 Healthcare Conference, November 10-12, 2026Format: Fireside chat and one-on-one meetingsPresentation Date & Time: Wednesday, November 11 at.

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time.

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto's finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto's founder, chief executive officer and c.

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead of it,” said A.

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications

Alto Neuroscience maintains a 'Buy' rating, driven by the potential of ALTO-207 for treatment-resistant depression [TRD] and robust cash reserves. ALTO-207, a pramipexole/ondansetron combination, targets TRD with phase 2b topline data expected in 2H 2027 and possible phase 3 initiation by early 2027. Despite ALTO-100's phase 2b failure in MDD, ANRO's diversified pipeline and biomarker-driven strategies support continued optimism.

Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected.

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden. Adults with elevated baseline anhedonia symptoms with a diagnosis of major d.

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. “We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuros.

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

See News Rankings

Price charts implemented using Lightweight Charts™